UBS AM’s Audentes Therapeutics, Inc BOLD Stock Holding History

UBS AM’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-34,753	Closed	-$2.08M	–	2570
2019 Q4	$2.08M	Sell	34,753 -250,714	-88%	-$9.41M	﹤0.01%	1590
2019 Q3	$8.02M	Buy	285,467 +5,953	+2%	+$203K	0.01%	1038
2019 Q2	$10.6M	Buy	279,514 +4,674	+2%	+$180K	0.01%	939
2019 Q1	$10.7M	Sell	274,840 -2,664	-1%	-$76.4K	0.01%	915
2018 Q4	$5.92M	Buy	277,504 +24,170	+10%	+$624K	0.01%	1032
2018 Q3	$10M	Buy	+253,334	New	+$9.44M	0.01%	934

UBS AM's BOLD Position: Q1 2020 in Review

UBS AM sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 34,753 shares — an estimated $2.08M sold.

UBS AM first reported a position in BOLD in Q3 2018 and held it in 6 quarters. The position peaked at $10.7M in Q1 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

UBS AM reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
UBS AM sold 34,753 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $2.08M.
UBS AM first reported a position in Audentes Therapeutics, Inc in Q3 2018 and held it in 6 quarters.
UBS AM's Audentes Therapeutics, Inc position peaked at $10.7M in Q1 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on UBS AM's 13F filing for Q1 2020, filed 15 May 2020.